MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine

British Journal of Clinical Pharmacology

Volumn 53, Issue 5, 2002, Pages 526-534

  Drescher, Siegfried ^a   Schaeffeler, Elke ^a   Hitzl, Monika ^a   Hofmann, Ute ^a   Schwab, Matthias ^a   Brinkmann, Ulrich ^c   Eichelbaum, Michel ^a,b   Fromm, Martin F ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Epidauros Biotechnologie AG   (Germany)

Author keywords

Fexofenadine; MDR1; P glycoprotein; Polymorphism; Rhodamine 123

Indexed keywords

FEXOFENADINE; GLYCOPROTEIN P; MEMBRANE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123; UNCLASSIFIED DRUG; CD56 ANTIGEN; DRUG DERIVATIVE; FLUORESCENT DYE; HISTAMINE H1 RECEPTOR ANTAGONIST; TERFENADINE;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; EXON; FEMALE; GENDER; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; MALE; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; BLOOD; CLINICAL TRIAL; DRUG EFFECT; GENE; GENETIC POLYMORPHISM; GENETICS; IN VITRO STUDY; METABOLISM; MONONUCLEAR CELL; SEX DIFFERENCE; URINE;

ANTIGENS, CD56; FEMALE; FLUORESCENT DYES; GENES, MDR; GENOTYPE; HISTAMINE H1 ANTAGONISTS; HUMAN; IN VITRO; LEUKOCYTES, MONONUCLEAR; MALE; P-GLYCOPROTEIN; POLYMORPHISM (GENETICS); RHODAMINE 123; RNA, MESSENGER; SEX FACTORS; SUPPORT, NON-U.S. GOV'T; TERFENADINE; HUMANS; POLYMORPHISM, GENETIC;

EID: 0035999902     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01591.x     Document Type: Article

References (36)

1. What have we learnt thus far from mice with disrupted P-glycoprotein genes?
2. P-glycoprotein and multidrug resistance
3. P-glycoprotein. A defense mechanism limiting oral bioavailability and CNS accumulation of drugs
4. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
5. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
6. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein
7. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
8. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
9. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil
10. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction
11. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
12. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
13. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
14. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
15. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells
16. OATP P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine
17. Fexofenadine. A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria
18. Clinical pharmacology of new histamine H1 receptor antagonists
19. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
20. The effect of rifampin administration on the disposition of fexofenadine
21. Genetic polymorphism in MDR-1. A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors
22. Identification of functionally variant MDR1 alleles among European Americans and African Americans
23. Determination of fexofenadine in human plasma and urine by liquid chromatography - Mass spectrometry
24. Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection
25. MDR1 pharmacogenetics: Frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity
26. Frequency of C3435T polymorphism of MDR1 gene in African people
27. Organic Anion-Transporting Polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver
28. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans
29. Modulation by dietary salt of verapamil disposition in humans
30. Fexofenadine bioavailability modulated by dietary salt
31. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes
32. Drug interactions with the nonsedating antihistamines
33. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers
34. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers
35. Frequency of single nucleotide polymorphisms (SNPs) in the P-glycoprotein drug transporter MDR1 gene in Caucasians
36. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins